Shares in Novo Nordisk (NYSE:NVO) fell -9% this morning after the pharmaceutical company missed expectations on Wall Street with its 4th quarter results and lowered its outlook for 2017. The Danish company posted profits of 8.7 billion Danish kroner, or $1.26 billion USD, on sales of 29.57 billion kroner for the 3 months ended Dec. 31, for bottom-line growth of […]
MassDevice Earnings Roundup
Surmodics raises guidance, beats Q1 earnings
Shares in Surmodics (NSDQ:SRDX) rose today after the medical device maker met expectations on Wall Street with its fiscal 2017 1st quarter results. The Eden Prairie, Minn.-based company posted profits of $2.3 million, or 17¢ per share, on sales of $17.8 million for the 3 months ended Dec. 31, for bottom-line loss of -13.3% on […]
Roche denies rumors it will shop diabetes unit, earnings
Roche (PINK:RHHBY) denied rumors that it was considering selling its diabetes unit today, saying that it is “committed” to the business. The company also predicted that competition and spending on new drugs would stall its margin growth in 2017, as patents expire for its blockbuster medications. The Swiss drugmaker’s 3 top-selling cancer drugs, Rituxan, Herceptin and […]
Eli Lilly posts mixed Q4 earnings
Shares in Eli Lilly (NYSE:LLY) rose today after the drug manufacturer missed earnings expectations, but beat revenue estimates on Wall Street with its 4th quarter results. The Indianapolis-based company posted profits of $771.8 million on sales of $5.76 billion for the 3 months ended Dec. 31, for bottom-line growth of 61.3% on sales growth of 7.1% compared […]
Pfizer misses on Q4 earnings
Shares in Pfizer (NYSE:PFE) remained steady today after the pharmaceutical company missed expectations on Wall Street with its 4th quarter results. The U.S. pharma giant posted profits of $775 million, or 13¢ per share, for the 3 months ended December 31, 2016, compared to a bottom-line loss of $172 million in the same period last year. Pfizer also reported revenues of $13.63 billion, a […]
Celgene acquires Delinia, beats on Q4 earnings
Shares in Celgene (NSDQ:CELG) fell yesterday, even though the biopharmaceutical company beat earnings expectations on Wall Street with its 4th quarter results. The Summit, N.J.-based company posted profits of $1.29 million, or $1.61 per share, on sales of $2.9 million for the 3 months ended Dec. 31, for bottom-line growth of 34% on sales growth […]
Johnson & Johnson’s earnings disappoint, but pharma rev climbs
Shares in Johnson & Johnson (NYSE:JNJ) fell this week after the company missed the consensus top-line forecasts but pulled off earnings beats for both the 4th quarter and 2016. Pharmaceutical sales grew 6.5% for the full-year to $33.5 billion, with an operational increase of 7.4%. Domestic sales climbed nearly 10% and international sales increased 1.8%. New Brunswick, […]
Biogen beats Q4 earnings, misses on full-year rev forecast
Shares in Biogen (NSDQ:BIIB) rose this week after the biopharmaceutical company met expectations on Wall Street with its 4th quarter financial results, but pegged its full-year revenue forecast lower than analysts expected. The Cambridge, Mass.-based company posted profits of $649.2 million, or $2.99 per share, on sales of $2.87 billion for the 3 months ended Dec. […]
Mylan’s Q3 misses on $465 million Medicaid settlement
Shares in Mylan (NDSQ:MYL) rose slightly today after the pharmaceutical giant missed expectations on Wall Street with its 3rd-quarter results. The Canonsburg, Pa.-based company posted a net loss of -$119.8 million, or -23¢ per share, on sales of $3.06 billion for the 3 months ended Sept. 30, for a bottom-line slide of -3% on sales growth of 14.2% […]
Clearside tops Q3 estimates, posts license revenue
Shares in Clearside Biomedical (NSDQ:CLSD) rose today after the biopharmaceutical company met expectations on Wall Street with its 3rd quarter results. The Alpharetta, Ga.-based company posted losses of -$5.6 million, or -28¢ per share, on sales of $5,000 for the 3 months ended Sept. 30. This is the 1st quarter that Clearside has reported revenue. Adjusted to exclude […]
